SCHEMBL10028014

SCHEMBL10028014

CCCCOCC(COCC(COCCCO)OCCCO)OCCCO

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 7/20 0.51
LPAR3 Q9UBY5 7/20 0.51
LPAR2 Q9HBW0 4/20 0.51
TSHR P16473 1/20 0.50
USP2 O75604 1/20 0.44
TLR2 O60603 2/20 0.41
HTT P42858 2/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 1/20 0.41
LPAR6 P43657 3/20 0.41
LPAR4 Q99677 3/20 0.41
LPAR5 Q9H1C0 3/20 0.41
ALDH1A1 P00352 2/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
DNM1 Q05193 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12047469 1.00 LPAR1 (0.51) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL12047466 0.94 LPAR1 (0.47) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL12047468 0.94 LPAR1 (0.47) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL12047460 0.91 LPAR1 (0.45) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL14616861 0.91 HSD17B10 (0.50) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL12047464 0.91 LPAR1 (0.45) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL12301807 0.91 LPAR1 (0.45) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL11314764 0.90 LPAR1 (0.63) LPAR1LPAR3LPAR2USP2TLR2
SCHEMBL12047457 0.90 TSHR (0.43) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL8953351 0.89 LPAR1 (0.46) LPAR1LPAR3LPAR2TSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110559-B2 Hindered ester-based biodegradable linkers for oligonucleotide delivery ENZON PHARMACEUTICALS, INC. (US) 2012-02-07 US disclosed
US-20100234444-A1 HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY ENZON PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-7625898-B2 Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof ENZON PHARMACEUTICALS, INC. (US) 2009-12-01 US disclosed
US-20090202573-A1 POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES ENZON PHARMACEUTICALS, INC. (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090202573-A1 POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES PIGO, PHOSPHO1, PAICS LPAR1 252/4885LPAR3 42/4885LPAR2 239/4885
US-20100234444-A1 HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY VEGFA, DCLRE1B, MSN LPAR1 530/4885LPAR3 302/4885LPAR2 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.